Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
European Hematology Association (EHA) 2019 Annual Meeting
June 13 - 16, 2019; Amsterdam, The Netherlands
June 13 - 16, 2019Amsterdam, The Netherlands
EHA 2019Novel Drug Targets Lymphoma Cells' 'Don't Eat Me' SignalThe first-in-class agent Hu5F9 is a macrophage immune checkpoint inhibitor and, when added onto rituximab, shows potentially long-lasting efficacy in patients with relapsed and refractory lymphoma.
EHA 2019Measurable Residual Disease in AML Ups Post-HSCT Relapse RiskMeasurable residual disease, detected with next-generation genomic sequencing, is associated with a significantly increased risk for relapse. Experts question the prognostic ability of other assessment tools.
New Drug for PHN Taken Only Once Every 8 WeeksRavulizumab, a new drug for paroxysmal nocturnal hemoglobinuria (PNH), requires IV infusion only once every 8 weeks, compared
with every 2 weeks for eculizumab, the only drug currently approved for this disorder.
Medscape Medical News, Jul 02, 2018
Novel Nonchemo Combo (Len-R) Effective in Follicular LymphomaA novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the
standard combination of rituximab and chemotherapy in the RELEVANCE trial.